// App-Quantinova.ai

: Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

Researchers

Presenter

  • Kristin B. Highland

Principal Investigators

  • Masataka Kuwana

  • Arata Azuma

  • Aryeh Fischer

  • Toby M. Maher

  • Maureen D. Mayes

  • Ganesh Raghu

  • Mannaig Girard

  • Veronika Kohlbrenner

  • Emmanuelle Clerisme-Beaty

  • Margarida Alves

  • Oliver Distler

Medical Centers

  • Medicine Institute, Cleveland Clinic, Cleveland, Ohio, United States

  • Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

  • University of Colorado School of Medicine, Denver, Colorado, United States of America

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

  • Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX

  • University of Washington, Washington, United States of America

  • Boehringer Ingelheim France S.A.S., Paris, France

  • Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, United States of America

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Locations

  • United States

  • Japan

  • United Kingdom

  • France

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved